Navigation Links
Response Biomedical Named Medical Device Company of the Year by LifeSciences British Columbia
Date:3/9/2009

VANCOUVER, March 9 /PRNewswire-FirstCall/ - Response Biomedical Corporation (TSX: RBM, OTCBB: RPBIF) announced that it has been named the Medical Device Company of the Year by LifeSciences British Columbia. This award is presented annually by LifeSciences British Columbia to recognize an organization that has made outstanding contributions to the development of British Columbia's life sciences industry and to increase public awareness and understanding of life sciences in the province. This particular award recognizes a company for execution of business strategies, scientific excellence, leadership and vision and market position/opportunity.

"We are very pleased to be recognized for the contribution and efforts of our whole team in 2008," said S. Wayne Kay, Chief Executive Officer. "We believe we have made outstanding progress in the development, regulatory approval and partnering of our key products in the areas of infectious diseases and cardiovascular diagnostic tests and this award is very much appreciated. There are many fine companies in the life sciences sector in British Columbia and we appreciate being acknowledged amongst our peers for standing out in the achievement of major milestones last year."

About Response Biomedical

Response Biomedical develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP(R) Platform for clinical and environmental applications. RAMP(R) represents a new paradigm in diagnostics that provides high sensitivity and reliable information in minutes. It is ideally suited to both point of care testing and laboratory use.

The RAMP(R) system consists of a Reader and single-use disposable test cartridges, and has the potential to be adapted to more than 250 medical and non-medical tests currently performed in laboratories. RAMP(R) clinical tests are commercially available for the early detection of heart attack, congestive heart failure and influenza.

In the non-clinical market, RAMP(R) Tests are currently provided for the environmental detection of West Nile Virus, and Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin. Several other product applications are under development. Response has achieved CE Marking for its Reader and clinical tests and its Quality Management System is registered to ISO 13485: 2003 and ISO 9001: 2000. The RAMP(R) Influenza A/B Assay and RAMP 200 reader are not yet licensed for clinical use in Canada.

Response Biomedical is a publicly traded company, listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

About LifeSciences British Columbia

LifeSciences British Columbia supports and represents the biopharmaceutical, medical device, bioproducts, bioenergy, and greater life sciences community of British Columbia through leadership, advocacy and promotion of British Columbia's world-class science and industry. Via active facilitation of partnering and investment into the life sciences sector, British Columbia is fast becoming a global life sciences leader. LifeSciences British Columbia is a not-for-profit, non-government, industry-funded association.


'/>"/>
SOURCE Response Biomedical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AdvaMed Response to the Medical Device Safety Act
2. Ethnicity May Drive Response to Obesity, Insulin Resistance
3. Study Showing Improved Virologic Response with Nitazoxanide in Chronic Hepatitis C Published in Gastroenterology
4. Preparing for the Next Disaster: Dialysis Community Briefs Hill About Emergency Response
5. Statement by American Heart Association President Timothy Gardner, M.D. in Response to Health Proposals in President Obamas Budget
6. Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government
7. Blunt Response to President Obamas Address
8. St John Ambulance Selects Web-Based SMS Solution From Text Messaging Centre (TMC) for Rapid Response Communication via Two-Way SMS Messaging
9. Team learns how cellular protein detects viruses and sparks immune response
10. Legion Condemns Governors Non-Response to ISSCH Proposal As Slap In The Face
11. FDA Clears New Immune Response Claim for the CryoValve(R) SG Pulmonary Human Heart Valve
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of ... report to their offering. ... kidney failure, it replaces the function of kidneys by removing ... thus the treatment helps to keep the patient body,s electrolytes ... Increasing number of ESRD patients & substantial healthcare expenditure ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
Breaking Medicine Technology: